Open AccessLong-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease
Author(s) -
Ryoji Maekura,
Keisuke Miki,
Yoshitaka Tateishi,
Sohkichi Matsumoto,
Shuichi Kitada,
Mari Miki,
Hiroshi Kida
Publication year - 2022
Publication title -
microbiology spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.502
H-Index - 51
ISSN - 2165-0497
DOI - 10.1128/spectrum.00530-22
Subject(s) - antimycobacterial , medicine , disease , mycobacterium , chemotherapy , mycobacterium avium complex , glycolipid , natural history , tuberculosis , biomarker , pulmonary disease , immunology , mycobacterium tuberculosis , biology , pathology , genetics
The natural history of MAC-PD is challenging to predict in immunocompetent patients at diagnosis, and the current multidrug chemotherapy options are not strong enough to eliminate mycobacteria from the lungs. Therefore, the diagnosis of MAC-PD does not necessarily lead to the decision to start chemotherapy.